DOCSLIB.ORG

Appendix AI (Administrative Instructions Under the PCT)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Appendix AI (Administrative Instructions Under the PCT) Appendix AI Administrative Instructions Under the PCT (as in force from July 1, 2019) TABLE OF CONTENTS 1 PART 1 INSTRUCTIONS RELATING Section 204 Headings of the Parts of the TO GENERAL MATTERS Description Section 204 bis Numbering of Claims Section 101 Abbreviated Expressions and Section 205 Numbering and Identi®cation of Interpretation Claims upon Amendment Section 102 Use of the Forms Section 206 Unity of Invention Section 102 bis [Deleted] Section 207 Arrangement of Elements and Section 103 Languages of the Forms Used Numbering of Sheets of the by International Authorities International Application Section 104 Language of Correspondence Section 208 Sequence Listings Section 105 Identi®cation of International Section 209 Indications as to Deposited Application with Two or More Biological Material on a Applicants Separate Sheet Section 106 Change of Common Section 210 [Deleted] Representative Section 211 Declaration as to the Identity of Section 107 Identi®cation of International the Inventor Authorities and of Designated Section 212 Declaration as to the Applicant's and Elected Of®ces Entitlement to Apply for and Be Section 108 Correspondence Intended for the Granted a Patent Applicant Section 213 Declaration as to the Applicant's Section 109 File Reference Entitlement to Claim Priority of Section 110 Dates Earlier Application Section 111 Procedure and Considerations Section 214 Declaration of Inventorship in the Case of Excuse of the Section 215 Declaration as to Delay in Meeting Certain Time Non-Prejudicial Disclosures or Limits under Rule 82 quater Exceptions to Lack of Novelty Section 112 Ceasing of Effect under Articles Section 216 Notice of Correction or Addition 24(1)(iii) and 39(2), Review of a Declaration under Rule under Article 25(2) and 26ter Maintaining of Effect under Section 217 Corrections Concerning Articles 24(2) and 39(3) Expressions, Etc., Not to Be Section 113 Special Fees Payable to the Used in the International International Bureau Application under Rule 9.2 Section 114 [Deleted] Section 218 Processing of a Request for Section 115 Indications of States, Territories Omission of Information and Intergovernmental Referred to in Rules 48.2(l) and Organizations 94.1(e) PART 2 INSTRUCTIONS RELATING PART 3 INSTRUCTIONS RELATING TO THE INTERNATIONAL TO THE RECEIVING APPLICATION OFFICE Section 201 Language of the International Section 301 Noti®cation of Receipt of Application Purported International Section 202 [Deleted] Application Section 203 Different Applicants for Section 302 Priority Claim Considered Not Different Designated States to Have Been Made 1 Table of Contents and Editor©s Notes are added for the convenience of the reader; they do not form part of the Administrative Instructions. AI-1 June 2020 MANUAL OF PATENT EXAMINING PROCEDURE Section 303 Deletion of Additional Matter Section 313 Documents Filed with the in the Request International Application; Section 304 Invitation to Pay Fees before Manner of Marking the Date on Which They Are Due Necessary Annotations in the Section 305 Identifying the Copies of the Check List International Application Section 314 Correction or Addition of a Section 305 bis Preparation, Identi®cation and Priority Claim Under Rule Transmittal of the Copies of the 26 bis Translation of the International Section 315 Processing of Documents by the Application Receiving Of®ce under Rule Section 305 ter Identi®cation and Transmittal 26 bis.3(h- bis) of the Translation of an Earlier Section 316 Procedure in the Case Where the Application Furnished under International Application Lacks Rule 20.6(a)(iii) the Prescribed Signature Section 306 Delayed Transmittal of Search Section 317 Transmittal of a Notice of Copy Correction or Addition of a Section 307 System of Numbering Declaration under Rule 26ter.1 International Applications Section 318 Cancellation of Designations of Section 308 Marking of the Sheets of the Non-Contracting States International Application and of Section 319 Procedure under Rule 4.9(b) the Translation Thereof Section 320 Invitation to Pay Fees under Section 308 bis Marking of Later Submitted Rule 16 bis.1(a) Sheets Section 321 Application of Moneys Section 309 Procedure in the Case of Later Received by the Receiving Submitted Sheets Furnished for Of®ce in Certain Cases the Purposes of Incorporation Section 322 Invitation to Submit a Request by Reference for Refund of the Search Fee Section 310 Procedure in the Case of Later Section 323 Transmittal of Priority Submitted Sheets Not Furnished Documents to International for the Purposes of Bureau Incorporation by Reference Section 324 Copy of Noti®cation of the Section 310 bis Procedure in the Case of Later International Application Submitted Sheets Resulting in Number and the International the Correction of the Filing Date under Rule 20.2(c) International Filing Date under Section 325 Corrections of Defects under Rule 20.5(c) Rule 26.4 and Recti®cations of Section 310 ter Procedure in the Case of Later Obvious Mistakes under Rule Submitted Sheets Furnished 91 after the Expiration of the Section 326 Withdrawal by Applicant under Applicable Time Limit Referred Rule 90 bis.1, 90 bis.2 or to in Rule 20.7 90 bis.3 Section 311 Renumbering in the Case of Section 327 Ex Of®cio Correction of Deletion, Substitution or Request by the Receiving Of®ce Addition of Sheets of the Section 328 Noti®cations Concerning International Application and of Representation the Translation Thereof Section 329 Correction of Indications Section 312 Noti®cation of Decision Not to Concerning the Applicant's Issue Declaration that the Residence or Nationality International Application Is Section 330 Transmittal of Record Copy Considered Withdrawn Prevented or Delayed by National Security Prescriptions June 2020 AI-2 ADMINISTRATIVE INSTRUCTIONS UNDER THE PCT Section 331 Receipt of Con®rmation Copy Section 411 bis Receipt of Translation of Earlier Section 332 Noti®cation of Languages Application under Rule Accepted by the Receiving 20.6(a)(iii) Of®ce under Rules 12.1(a) and Section 412 Noti®cation of Lack of (c) and 12.4(a) Transmittal of Search Copy Section 333 Transmittal of International Section 413 Incorporations by Reference Application to the International under Rule 20, Corrections of Bureau as Receiving Of®ce Defects under Rule 26.4 and Section 334 Noti®cation to Applicant of Recti®cations of Obvious Submission of Demand after the Mistakes under Rule 91 Expiration of 19 Months from Section 413 bis Recti®cations of Obvious the Priority Date Mistakes under Rule 91 Section 335 [Deleted] Section 414 Noti®cation to the International Section 336 Waivers under Rules 90.4(d) Preliminary Examining and 90.5(c) Authority Where the Section 337 [Deleted] International Application is PART 4 INSTRUCTIONS RELATING Considered Withdrawn TO THE INTERNATIONAL Section 415 Noti®cation of Withdrawal BUREAU under Rule 90 bis.1, 90 bis.2, 90 bis.3, 90 bis.3 bis or 90 bis.4 Section 401 Marking of the Sheets of the Section 416 Correction of Request in Record Record Copy Copy Section 402 Correction or Addition of a Section 417 Processing of Amendments Priority Claim under Rule 26 bis under Article 19 Section 403 Transmittal of Protest against Section 418 Noti®cations to Elected Of®ces Payment of Additional Fees and Where the Demand Is Decision Thereon Where Considered Not to Have Been International Application Is Submitted or Made Considered to Lack Unity of Section 419 Processing of a Declaration Invention under Rule 26 ter Section 404 International Publication Section 420 Copy of International Number of International Application, International Application Search Report and Section 405 Publication of Noti®cations of Supplementary International Languages Accepted by the Search Report for the Receiving Of®ce under Rules International Preliminary 12.1(a) and (c) and 12.4(a) Examining Authority Section 406 Publication of International Section 421 Invitation to Furnish a Copy of Applications the Priority Document Section 406 bis Suggested English Translation Section 422 Noti®cations Concerning of the Title of the Invention Changes Recorded under Rule Section 407 The Gazette 92 bis.1 Section 408 Priority Application Number Section 422 bis Objections Concerning Changes Section 409 Priority Claim Considered Not in the Person of the Applicant to Have Been Made Recorded under Rule 92 bis.1(a) Section 410 Numbering of Sheets for the Section 423 Cancellation of Designations Purposes of International and Elections Publication; Procedure in Case Section 424 Procedure under Rule 4.9(b) of Missing Sheets Section 425 Noti®cations Concerning Section 411 Receipt of Priority Document Representation Section 426-429 [Deleted] AI-3 June 2020 MANUAL OF PATENT EXAMINING PROCEDURE Section 430 Noti®cation of Designations Searching Authority on the under Rule 32 Basis of a Translation of the Section 431 Publication of Notice of International Application Submission of Demand Section 510 Refund of Search Fee in Case of Section 432 Noti®cation to Applicant of Withdrawal of International Submission of Demand after the Application Expiration of 19 Months from Section 511 Recti®cations of Obvious the Priority Date Mistakes under Rule 91 Section 433 Waivers under Rule 90.4(d) Section 512 Noti®cations Concerning Section 434 Publication of Information Representation Concerning Waivers under Section 513 Sequence Listings Rules 90.4(d) and 90.5(c) Section 514 Authorized Of®cer Section 435 Communication of Publications Section 515 Modi®cation of Abstract in and Documents Response to Applicant's
Load more

Recommended publications
  • Preferential Import of Queuosine-Modified Trnas Into
    Published online 9 July 2021 Nucleic Acids Research, 2021, Vol. 49, No. 14 8247–8260 https://doi.org/10.1093/nar/gkab567 Preferential import of queuosine-modified tRNAs into Trypanosoma brucei mitochondrion is critical for organellar protein synthesis Sneha Kulkarni1,2, Mary Anne T. Rubio1,3,EvaHegedusov˝ a´ 1, Robert L. Ross4, Patrick A. Limbach 5, Juan D. Alfonzo3 and Zdenekˇ Paris 1,2,* 1Institute of Parasitology, Biology Centre, Czech Academy of Sciences, Ceskˇ eBud´ ejovice,ˇ Czech Republic, 2Faculty 3 of Science, University of South Bohemia, Ceskˇ eBud´ ejovice,ˇ Czech Republic, Department of Microbiology and The Downloaded from https://academic.oup.com/nar/article/49/14/8247/6318497 by guest on 01 October 2021 Center for RNA Biology, The Ohio State University, Columbus, OH, USA, 4Metabolomics Mass Spectrometry Core, Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA and 5Rieveschl Laboratories for Mass Spectrometry, Department of Chemistry, University of Cincinnati, Cincinnati, OH, USA Received November 30, 2020; Revised May 28, 2021; Editorial Decision June 13, 2021; Accepted June 21, 2021 ABSTRACT sine (Q), a hypermodified 7-deaza-guanosine, is one of the most chemically intricate modifications described to date. Transfer RNAs (tRNAs) are key players in protein syn- Q is found at the wobble position 34 of tRNAs that contain thesis. To be fully active, tRNAs undergo extensive a5-GUN-3 anticodon sequence, where N represents any post-transcriptional modifications, including queuo- of the canonical nucleotides, which includes tRNAHisGUG, sine (Q), a hypermodified 7-deaza-guanosine present tRNAAspGUC, tRNAAsnGUU, tRNATyr GUA (3). Q is in the anticodon of several tRNAs in bacteria and eu- found in both bacteria and eukarya, and catalyzed by tRNA karya.
    [Show full text]
  • Discovery of Novel Bacterial Queuine Salvage Enzymes and Pathways in Human Pathogens
    Discovery of novel bacterial queuine salvage enzymes and pathways in human pathogens a,1 b,1 c,1 b d a Yifeng Yuan , Rémi Zallot , Tyler L. Grove , Daniel J. Payan , Isabelle Martin-Verstraete , Sara Sepic´ , Seetharamsingh Balamkundue, Ramesh Neelakandane, Vinod K. Gadie, Chuan-Fa Liue, Manal A. Swairjof,g, Peter C. Dedone,h,i, Steven C. Almoc, John A. Gerltb,j,k, and Valérie de Crécy-Lagarda,l,2 aDepartment of Microbiology and Cell Science, University of Florida, Gainesville, FL 32611; bInstitute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, IL 61801; cDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461; dLaboratoire de Pathogénèse des Bactéries Anaérobies, Institut Pasteur et Université de Paris, F-75015 Paris, France; eSingapore-MIT Alliance for Research and Technology, Infectious Disease Interdisciplinary Research Group, 138602 Singapore, Singapore; fDepartment of Chemistry and Biochemistry, San Diego State University, San Diego, CA 92182; gThe Viral Information Institute, San Diego State University, San Diego, CA 92182; hDepartment of Biological Engineering and Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139; iCenter for Environmental Health Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139; jDepartment of Biochemistry, University of Illinois at Urbana–Champaign, Urbana, IL 61801; kDepartment of Chemistry, University of Illinois at Urbana–Champaign, Urbana, IL 61801; and lUniversity of Florida Genetics Institute, Gainesville, FL 32610 Edited by Tina M. Henkin, The Ohio State University, Columbus, OH, and approved August 1, 2019 (received for review June 16, 2019) Queuosine (Q) is a complex tRNA modification widespread in 1A. The TGT enzyme, which is responsible for the base ex- eukaryotes and bacteria that contributes to the efficiency and accuracy change, is the signature enzyme in the Q biosynthesis pathway.
    [Show full text]
  • Queuine, a Bacterial Derived Hypermodified Nucleobase, Shows Protection in in Vitro Models of Neurodegeneration
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427538; this version posted January 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Queuine, a bacterial derived hypermodified nucleobase, shows protection in in vitro models of neurodegeneration Patricia Richard1*, Xavier Manière2*, Lucie Kozlowski2, Hélène Guillorit2,3, Patrice Garnier2, Antoine Danchin4, Nicole C. McKnight1** 1 Stellate Therapeutics Inc., 101 Avenue of the Americas, JLABS @ NYC, New York, NY 10013 2 Stellate Therapeutics SAS, 47 rue de Montmorency, 75003, Paris, France 3 Institut de Génomique Fonctionnelle, 141 rue de la Cardonille, 34094, Montpellier, France 4 Kodikos Labs, Institut Cochin, 24 rue du Faubourg Saint-Jacques, 75014, Paris, France ** corresponding author Email: [email protected] * These authors contributed equally to this work 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427538; this version posted January 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Growing evidence suggests that human gut bacteria, comprising the microbiome that communicates with the brain through the so-called ‘gut-brain-axis’, are linked to neurodegener- ative disorders. Imbalances in the microbiome of Parkinson’s disease (PD) and Alzheimer’s dis- ease (AD) patients have been detected in several studies. Queuine is a hypermodified nucleobase enriched in the brain and exclusively produced by bacteria and salvaged by humans through their gut epithelium. Queuine replaces guanine at the wobble position of tRNAs with GUN anticodons and promotes efficient cytoplasmic and mitochondrial mRNA translation.
    [Show full text]
  • Synthetic Ligands for Preq1 Riboswitches Provide Structural and Mechanistic Insights Into Targeting RNA Tertiary Structure
    ARTICLE https://doi.org/10.1038/s41467-019-09493-3 OPEN Synthetic ligands for PreQ1 riboswitches provide structural and mechanistic insights into targeting RNA tertiary structure Colleen M. Connelly1, Tomoyuki Numata2,3, Robert E. Boer1, Michelle H. Moon1, Ranu S. Sinniah1, Joseph J. Barchi1, Adrian R. Ferré-D’Amaré 2 & John S. Schneekloth Jr. 1 1234567890():,; Riboswitches are naturally occurring RNA aptamers that regulate gene expression by binding to specific small molecules. Riboswitches control the expression of essential bacterial genes and are important models for RNA-small molecule recognition. Here, we report the discovery of a class of synthetic small molecules that bind to PreQ1 riboswitch aptamers. These molecules bind specifically and reversibly to the aptamers with high affinity and induce a conformational change. Furthermore, the ligands modulate riboswitch activity through tran- scriptional termination despite no obvious chemical similarity to the cognate ligand. X-ray crystallographic studies reveal that the ligands share a binding site with the cognate ligand but make different contacts. Finally, alteration of the chemical structure of the ligand causes changes in the mode of RNA binding and affects regulatory function. Thus, target- and structure-based approaches can be used to identify and understand the mechanism of synthetic ligands that bind to and regulate complex, folded RNAs. 1 Chemical Biology Laboratory, National Cancer Institute, Frederick, MD 21701, USA. 2 Biochemistry and Biophysics Center, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA. 3 Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8566, Japan. These authors contributed equally: Colleen M.
    [Show full text]
  • Protection of the Queuosine Biosynthesis Enzyme Quef from Irreversible Oxidation by a Conserved Intramolecular Disulfide
    biomolecules Article Protection of the Queuosine Biosynthesis Enzyme QueF from Irreversible Oxidation by a Conserved Intramolecular Disulfide Adeba Mohammad 1, Adriana Bon Ramos 2, Bobby W. K. Lee 2, Spencer W. Cohen 2, Maryam K. Kiani 1, Dirk Iwata-Reuyl 2, Boguslaw Stec 3 and Manal A. Swairjo 1,3,* 1 Graduate College of Biomedical Sciences, Western University of Health Sciences, 309 E. Second Street, Pomona, CA 91766, USA; [email protected] (A.M.); [email protected] (M.K.K.) 2 Department of Chemistry, Portland State University, P.O. Box 751, Portland, OR 97207, USA; [email protected] (A.B.R.); [email protected] (B.W.K.L.); [email protected] (S.W.C.); [email protected] (D.I.-R.) 3 Department of Chemistry and Biochemistry, San Diego State University 5500 Campanile Drive, San Diego, CA 92182, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-619-206-3864 Academic Editor: Jürg Bähler Received: 10 January 2017; Accepted: 10 March 2017; Published: 16 March 2017 Abstract: QueF enzymes catalyze the nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of the nitrile group of 7-cyano-7-deazaguanine (preQ0) to 7-aminomethyl-7-deazaguanine (preQ1) in the biosynthetic pathway to the tRNA modified nucleoside queuosine. The QueF-catalyzed reaction includes formation of a covalent thioimide intermediate with a conserved active site cysteine that is prone to oxidation in vivo. Here, we report the crystal structure of a mutant of Bacillus subtilis QueF, which reveals an unanticipated intramolecular disulfide formed between the catalytic Cys55 and a conserved Cys99 located near the active site.
    [Show full text]
  • MODOMICS: a Database of RNA Modification Pathways. 2017 Update
    Published online 2 November 2017 Nucleic Acids Research, 2018, Vol. 46, Database issue D303–D307 doi: 10.1093/nar/gkx1030 MODOMICS: a database of RNA modification pathways. 2017 update Pietro Boccaletto1,†, Magdalena A. Machnicka1,2,†, Elzbieta Purta1,Pawe-lPiatkowski˛ 1, B-lazej˙ Baginski´ 1, Tomasz K. Wirecki1,Valerie´ de Crecy-Lagard´ 3, Robert Ross4,Patrick A. Limbach4, Annika Kotter5, Mark Helm5 and Janusz M. Bujnicki1,6,* 1Laboratory of Bioinformatics and Protein Engineering, International Institute of Molecular and Cell Biology in Warsaw, ul. Ks. Trojdena 4, PL-02-109 Warsaw, Poland, 2Institute of Informatics, University of Warsaw, Banacha 2, PL-02-097 Warsaw, Poland, 3Microbiology and Cell Science Department, University of Florida, Gainesville, FL 32611, USA, 4Department of Chemistry, Rieveschl Laboratories for Mass Spectrometry, University of Cincinnati, Cincinnati, OH 45221, USA, 5Institut fur¨ Pharmazie und Biochemie, Johannes Gutenberg-Universitat,¨ Staudinger Weg 5, D-55128 Mainz, Germany and 6Faculty of Biology, Adam Mickiewicz University, ul. Umultowska 89, PL-61-614 Poznan, Poland Received September 15, 2017; Revised October 15, 2017; Editorial Decision October 16, 2017; Accepted October 18, 2017 ABSTRACT for basic biological processes [review: (1)]. Now we know that 163 post-transcriptional modifications of RNA intro- MODOMICS is a database of RNA modifications duce a functional diversity that allows the four basic ribonu- that provides comprehensive information concern- cleotide residues to gain diverse functions, akin to those of ing the chemical structures of modified ribonucleo- side chains of amino acid residues, which may be e.g., po- sides, their biosynthetic pathways, the location of lar, charged, aliphatic or aromatic. Modifications can di- modified residues in RNA sequences, and RNA- rectly influence RNA structure, by promoting or disrupt- modifying enzymes.
    [Show full text]
  • ST.25 Page: 3.25.1
    HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION Ref.: Standards – ST.25 page: 3.25.1 STANDARD ST.25 STANDARD FOR THE PRESENTATION OF NUCLEOTIDE AND AMINO ACID SEQUENCE LISTINGS IN PATENT APPLICATIONS Revision adopted by the SCIT Standards and Documentation Working Group at its eleventh session on October 30, 2009 It is recommended that Offices apply the provisions of the “Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in International Patent Applications Under the Patent Cooperation Treaty (PCT)” as set out in Annex C to the Administrative Instructions under the PCT, mutatis mutandis, to all patent applications other than the PCT international applications, noting that certain provisions specific to PCT procedures and requirements may not be applicable to patent applications other than PCT international applications(*). The text of that PCT Standard is reproduced on the following pages. (*) If, on July 1, 2009, the national law and practice applicable by an Office is not compatible with the provisions of paragraph 3(i) of the “Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in International Patent Applications Under the Patent Cooperation Treaty (PCT)” requiring that a sequence listing which is contained in the international application as filed “shall be presented as a separate part of the description, be placed at the end of the application, preferably be entitled ‘Sequence Listing’, begin on a new page and have independent page numbering”, that Office may choose not to follow those provisions for as long as that incompatibility continues. en / 03-25-01 Date: December 2009 HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION Ref.: Standards – ST.25 page: 3.25.2 ANNEX C STANDARD FOR THE PRESENTATION OF NUCLEOTIDE AND AMINO ACID SEQUENCE LISTINGS IN INTERNATIONAL PATENT APPLICATIONS UNDER THE PCT INTRODUCTION 1.
    [Show full text]
  • Queuosine Deficiency in Eukaryotes Compromises Tyrosine Production Through Increased Tetrahydrobiopterin Oxidation
    JBC Papers in Press. Published on April 12, 2011 as Manuscript M111.219576 The latest version is at http://www.jbc.org/cgi/doi/10.1074/jbc.M111.219576 QUEUOSINE DEFICIENCY IN EUKARYOTES COMPROMISES TYROSINE PRODUCTION THROUGH INCREASED TETRAHYDROBIOPTERIN OXIDATION Tatsiana Rakovich‡, Coilin Boland‡, Ilana Bernstein§, Vimbai M. Chikwana¶, Dirk Iwata-Reuyl¶, and Vincent P. Kelly‡ From the ‡School of Biochemistry & Immunology, Trinity College Dublin, Dublin 2, Ireland, §School of Environmental & Life Sciences, University of Newcastle, Callaghan, NSW, 2308, Australia, and ¶Department of Chemistry, Portland State University, Portland, Oregon 97207 Running head: Queuosine deficiency leads to elevated dihydrobiopterin Address correspondence to: Vincent Kelly, Ph.D., School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland. Tel: +353-1-8963507; Fax: 81-298-53-7318; E-mail: [email protected] Queuosine is a modified pyrrolopyrimidine of complex carbohydrates to the provision of vital nucleoside found in the anticodon loop of micronutrients (1). Queuosine is an example of a transfer RNA acceptors for the amino acids micronutrient, synthesised exclusively by bacteria Downloaded from tyrosine, asparagine, aspartic acid, and but which, for poorly defined reasons, is utilised histidine. Since it is exclusively synthesised by by almost all eukaryotic species with the exception bacteria, higher eukaryotes must salvage of the baker’s yeast, S. cerevisiae (2). queuosine or its nucleobase queuine from food Bacterial queuosine biosynthesis occurs in two and the gut microflora. Previously, animals stages. Firstly, a series of five enzymatic steps www.jbc.org made deficient in queuine died within 18 days of convert guanosine triphosphate nucleoside (GTP) withdrawing tyrosine—a non-essential amino to the soluble 7-aminomethyl-7-deazaguanine acid—from the diet [Marks T, Farkas WR (preQ ) molecule.
    [Show full text]
  • Federal Register/Vol. 86, No. 100/Wednesday, May 26, 2021/Proposed Rules
    Federal Register / Vol. 86, No. 100 / Wednesday, May 26, 2021 / Proposed Rules 28301 DEPARTMENT OF COMMERCE comments. Attachments to electronic expected to have a minimal impact on comments will be accepted in ADOBE® applicants in general. Patent and Trademark Office portable document format or The USPTO encourages applicants to MICROSOFT WORD® format. Because file their patent applications via its 37 CFR Part 1 comments will be made available for USPTO patent electronic filing system and imposes a surcharge for non- [Docket No. PTO–P–2020–0032] public inspection, information that the submitter does not desire to make electronic filing of an original patent RIN 0651–AD48 public, such as an address or phone application (excluding reissue, design, number, should not be included in the plant, and provisional applications), as Electronic Submission of a Sequence comments. mandated by section 10(h) of Public Listing, a Large Table, or a Computer Visit the Federal eRulemaking Portal Law 112–29, September 16, 2011 Program Listing Appendix in Patent (Leahy-Smith America Invents Act). The Applications website (www.regulations.gov) for additional instructions on providing USPTO provides information (Legal AGENCY: United States Patent and comments via the portal. If electronic Framework for Patent Electronic Trademark Office, Department of submission of comments is not feasible System) concerning electronic filing via Commerce. due to lack of access to a computer and/ the USPTO patent electronic filing system on its website at www.uspto.gov/ ACTION: Notice of proposed rulemaking. or the internet, please contact the USPTO using the contact information patents-application-process/filing- SUMMARY: The United States Patent and below for special instructions.
    [Show full text]
  • A Truncated Aminoacyl–Trna Synthetase Modifies RNA
    A truncated aminoacyl–tRNA synthetase modifies RNA Juan C. Salazar*, Alexandre Ambrogelly*, Pamela F. Crain†, James A. McCloskey†‡, and Dieter So¨ ll*§¶ Departments of *Molecular Biophysics and Biochemistry, and §Chemistry, Yale University, New Haven, CT 06520-8114; and Departments of †Medicinal Chemistry and ‡Biochemistry, University of Utah, Salt Lake City, UT 84112-5820 Contributed by Dieter So¨ll, March 21, 2004 Aminoacyl–tRNA synthetases are modular enzymes composed of a tRNA in trans (11, 12), a mechanism that should increase the central active site domain to which additional functional domains fidelity of the translation process. were appended in the course of evolution. Analysis of bacterial Here we report the characterization of another widely distrib- genome sequences revealed the presence of many shorter amino- uted aaRS paralog, a glutamyl–tRNA synthetase (GluRS)- acyl–tRNA synthetase paralogs. Here we report the characteriza- related protein encoded by yadB in E. coli. tion of a well conserved glutamyl–tRNA synthetase (GluRS) paralog Materials and Methods (YadB in Escherichia coli) that is present in the genomes of >40 species of proteobacteria, cyanobacteria, and actinobacteria. The E. Oligonucleotides, DNA Sequencing, Radiochemicals, and Bacterial coli yadB gene encodes a truncated GluRS that lacks the C-terminal Strains. Oligonucleotides synthesis and DNAs sequencing was third of the protein and, consequently, the anticodon binding performed by the Keck Foundation Biotechnology Resource 14 domain. Generation of a yadB disruption showed the gene to be Laboratory at Yale University. Uniformly labeled [ C]Glu (254 ͞ ϭ 32 dispensable for E. coli growth in rich and minimal media. Unlike mCi mmol; 1 Ci 37 GBq), sodium [ P]pyrophosphate (1–60 ͞ ␥ 32 ͞ GluRS, the YadB protein was able to activate glutamate in presence Ci mmol), and [ - P]ATP (6,000 Ci mmol) were from Amer- 14 ͞ of ATP in a tRNA-independent fashion and to transfer glutamate sham Biosciences.
    [Show full text]
  • Detection and Quantification of Glycosylated Queuosine Modified
    Downloaded from rnajournal.cshlp.org on September 29, 2021 - Published by Cold Spring Harbor Laboratory Press Detection and quantification of glycosylated queuosine modified tRNAs by acid denaturing and APB gels Wen Zhang1, Ruyi Xu2,3, Żaneta Matuszek4, Zhen Cai2,3, Tao Pan4,* 1. Department of Chemistry, University of Chicago, Chicago, IL 60637, USA 2. Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou, China 3. Institute of Hematology, Zhejiang University, Zhejiang, China 4. Department of Biochemistry & Molecular Biology, University of Chicago, Chicago, IL 60637, USA *Corresponding author: [email protected] Keywords: Queuosine, Mannosyl-Queuosine, Galactosyl-Queuosine, Acid denaturing PAGE. 1 Downloaded from rnajournal.cshlp.org on September 29, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract: Queuosine (Q) is a conserved tRNA modification in bacteria and eukaryotes. Eukaryotic Q-tRNA modification occurs through replacing the guanine base with the scavenged metabolite queuine at the wobble position of tRNAs with G34U35N36 anticodon (Tyr, His, Asn, Asp) by the QTRT1/QTRT2 heterodimeric enzyme encoded in the genome. In humans, Q-modification in tRNATyr and tRNAAsp are further glycosylated with galactose and mannose, respectively. Although galactosyl-Q (galQ) and mannosyl-Q (manQ) can be measured by LC/MS approaches, the difficulty of detecting and quantifying these modifications with low sample inputs has hindered their biological investigations. Here we describe a simple acid denaturing gel and non- radioactive Northern blot method to detect and quantify the fraction of galQ/manQ-modified tRNA using just microgram amounts of total RNA. Our method relies on the secondary amine group of galQ/manQ becoming positively charged to slow their migration in acid denaturing gels commonly used for tRNA charging studies.
    [Show full text]
  • (Oq) Reductase Reveals Parallels Between Halorespiration and Trna Modification
    Discovery of epoxyqueuosine (oQ) reductase reveals parallels between halorespiration and tRNA modification Zachary D. Miles, Reid M. McCarty, Gabriella Molnar, and Vahe Bandarian1 Department of Chemistry and Biochemistry, University of Arizona, 1041 East Lowell Street, Tucson, AZ 85721-0088 Edited by Christopher T. Walsh, Harvard Medical School, Boston, MA, and approved March 10, 2011 (received for review December 15, 2010) Transfer RNA is one of the most richly modified biological mole- This in vitro reconstitution of the 7-deazapurine core was aided cules. Biosynthetic pathways that introduce these modifications by the discovery of the toyocamycin biosynthetic gene cluster in are underexplored, largely because their absence does not lead Streptomyces rimosus, which contains three genes that had been to obvious phenotypes under normal growth conditions. Queuo- previously shown to be required for the biosynthesis of queuosine sine (Q) is a hypermodified base found in the wobble positions in Bacillus subtilis (10–13). The cluster also contained a GTP of tRNA Asp, Asn, His, and Tyr from bacteria to mankind. Using cyclohydrolase I (GCH I) homolog, which hinted at GTP as being liquid chromatography MS methods, we have screened 1,755 sin- the primary metabolic precursor. GCH I catalyzes the conversion gle gene knockouts of Escherichia coli and have identified the key of GTP to 7,8-dihydroneopterin triphosphate (H2NTP) in the final step in the biosynthesis of Q. The protein is homologous to first step in the biosynthesis of both folic acid and biopterin. B12-dependent iron-sulfur proteins involved in halorespiration. GCH I was subsequently shown to be required for the biosynth- The recombinant Bacillus subtilis epoxyqueuosine (oQ) reductase esis of Q in Escherichia coli (14).
    [Show full text]